Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19
Retrieved on:
Monday, May 4, 2020
Health, Infectious diseases, Genetics, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biotechnology, Biology, RNA, Alnylam Pharmaceuticals, Therapeutic gene modulation, Gene expression, RNA interference, Severe acute respiratory syndrome-related coronavirus, Zoonoses, Severe acute respiratory syndrome, RNAI, VIR-2703 (ALN-COV), RNAi, Vir Biotechnology, Alnylam
With this DC selection, Vir and Alnylam will work closely together to generate the data required to enable rapid commencement of clinical studies.
Key Points:
- With this DC selection, Vir and Alnylam will work closely together to generate the data required to enable rapid commencement of clinical studies.
- Our fruitful and expansive collaboration with Alnylam has rapidly led to identification of a development candidate targeting SARS-CoV-2, said George Scangos, Ph.D., CEO of Vir.
- Im very proud of the quality and pace of work done by our scientists and with our collaborators at Vir to identify an RNAi therapeutic development candidate targeting the SARS-CoV-2 genome.
- VIR-2703 is the first development candidate selected in the companys expanded collaboration with Alnylam for up to four RNAi potential therapeutics for COVID-19.